14/06/2026
The 2026 American Diabetes Association Scientific Sessions just wrapped, and the shift in how we approach both technology and therapeutics is massive. 🩺✨
We are officially moving away from a fragmented approach to metabolic health. Technology like Automated Insulin Delivery (AID) is no longer a hurdle to jump through—it is the baseline. Meanwhile, incretin therapies are rewriting the rules, proving their benefits extend far beyond glycemic control into joint health, sleep, and cardiovascular protection.
Swipe through to read my full clinical breakdown of the biggest takeaways from ADA 2026, including the shift toward muscle preservation and the incredible new “triple-G” agonists coming down the pipeline.
Which of these updates are you most excited to see translated into daily clinical practice? Let me know below! 👇
[ADA2026, DiabetesCare, GLP1, HealthTech, Endocrinology, MedicalScience, EvidenceBased, MetabolicHealth, DoctorsofVadodara, LifestyleMedicine, KayakalpaClinic]